Ítem
Acceso Abierto

Plasma Levels of CXCL9 and MCP-3 are Increased in Asthma-COPD Overlap (ACO) Patients

Mostrar el registro sencillo de la publicación
dc.creatorAcevedo, Nathaliespa
dc.creatorCaraballo, Luisspa
dc.creatorGonzález-García, Mauriciospa
dc.creatorDennis Verano, Rodolfo Josespa
dc.creatorFlorez de Arco, Lucila Teresaspa
dc.creatorRegino, Ronaldspa
dc.creatorRamirez, Jonathan Camilospa
dc.creatorDe Vivero, María Mspa
dc.creatorProaños-Jurado, Nadia Julianaspa
dc.creatorLlinás-Caballero, Kevinspa
dc.creatorTorres-Duque, Carlos Aspa
dc.creatorEscamilla-Gil, Jose Miguelspa
dc.date.accessioned2025-07-21T16:51:34Z
dc.date.available2025-07-21T16:51:34Z
dc.date.created2025-04-22spa
dc.date.issued2025-04-22spa
dc.description.abstractPurpose: Asthma and chronic obstructive pulmonary disease overlap patients (ACO) have more exacerbations and a worse prognosis than pure asthma or COPD, and it is of great interest to identify differential biomarkers of ACO. We compared blood eosinophil counts, plasma IgE and protein levels among patients with asthma, ACO, COPD, and healthy subjects to identify those associated with ACO. Patients and Methods: 397 adults (age 40–90 years) were recruited from two Colombian cities: asthma (n=123), COPD (n=100), ACO (n=74) and healthy control (HC, n=100). Plasma protein levels were measured using the Proximity Extension Assay (Olink Proteomics). Results: There were no differences in blood eosinophil counts between the patient groups. Total and specified IgE levels were higher in patients with ACO than in those with COPD. Ten plasma proteins showed significant differences between the patients with ACO and HC. In patients above 60 years old, CXCL9 discriminates ACO from asthma patients with AUC 0.73 (0.63–0.82, DeLong test p=0.007), and in patients below 60 years old, MCP-3 discriminates ACO from COPD patients with AUC 0.84 (0.62–1.0, DeLong test p=0.006). CUB domain-containing protein 1 (CDCP1) levels (OR, 0.47; p=0.008) and age > 60 years (OR, 0.25; p=0.001) were negatively associated with ACO. Conclusion: CXCL9 levels could be used to discriminate ACO from asthma patients and MCP-3 to discriminate ACO from COPD. Protein inflammatory signatures in plasma of ACO patients were similar to the COPD group. This study revealed novel biomarkers that may help characterize patients with ACOeng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.2147/COPD.S506517spa
dc.identifier.issn1176-9106spa
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/46097
dc.language.isoengspa
dc.publisherDovepress Taylor & Francis Groupspa
dc.relation.ispartofInternational Journal of Chronic Obstructive Pulmonary Disease 2025:20spa
dc.relation.urihttps://www.dovepress.com/plasma-levels-of-cxcl9-and-mcp-3-are-increased-in-asthma-copd-overlap--peer-reviewed-fulltext-article-COPDspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accesoAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourceInternational Journal of Chronic Obstructive Pulmonary Diseasespa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordBiomarkerseng
dc.subject.keywordProximity Extension Assayeng
dc.subject.keywordPEAeng
dc.subject.keywordChronic Obstructive Pulmonary Diseaseeng
dc.subject.keywordCOPDeng
dc.subject.keywordCirculating Inflammatory Mediatorseng
dc.subject.keywordCXCL9eng
dc.subject.keywordMCP-3eng
dc.titlePlasma Levels of CXCL9 and MCP-3 are Increased in Asthma-COPD Overlap (ACO) Patientsspa
dc.typearticlespa
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersionspa
dc.type.spaArtículo de Investigaciónspa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
Plasma_Levels_of_CXCL9_and_MCP-3.pdf
Tamaño:
4.66 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos